C4 Therapeutics, Inc. CCCC
C4 Therapeutics, Inc. (Nasdaq: CCCC) is an oncology drug developer. Its lead program, cemsidomide, is in Phase 2 for relapsed/refractory multiple myeloma. Its next catalyst on record is cemsidomide (MOMENTUM Phase 2): Enrollment complete (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: cemsidomide (MOMENTUM Phase 2) — Enrollment complete (Q1 2027). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| cemsidomide | relapsed/refractory multiple myeloma | small molecule | Phase 2 |
| cemsidomide + dexamethasone + elranatamab | earlier lines of multiple myeloma treatment | small molecule | Phase 1 |
| CFT8919 | EGFR L858R mutant NSCLC | small molecule | Phase 1 |
| cemsidomide + dexamethasone + daratumumab or carfilzomib | multiple myeloma | small molecule | Pre-clinical |
Recent results and decisions
- Nov 5, 2026started Additional Phase 1b trial evaluating cemsidomide in combination with approved MM therapies on track to initiate in first half of 2027.
An additional Phase 1b trial evaluating cemsidomide across two treatment arms in RRMM patients is on track to initiate in the first half of 2027.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.